MYD88 and diffuse large B-cell lymphoma: This analysis also showed expected agreements across all comparisons including LME-IN and LE4 (κ = 0.47), both characterized by immune cell infiltration and inflammation, TME26 negative and LME-DE (κ = 0.43), both lacking immune cells, MCD with MYD88 (κ = 0.3), both of which harbor MYD88 mutations, and EZB with BCL2 (κ = 0.27), both classified by mutations in BCL2 and EZH2. Together, these data suggests that our new risk signature is unique and identifies high risk cases across existing DLBCL classifiers.